Hanna C, Etry H, Ibrahim M, Khalife L, Bahous S, Faour W
BMC Nephrol. 2025; 26(1):118.
PMID: 40045253
PMC: 11884025.
DOI: 10.1186/s12882-025-04039-w.
Mousavi S, Nouri S, Sadeghipour A, Atashi A
Ann Hematol. 2025; .
PMID: 39994019
DOI: 10.1007/s00277-025-06237-w.
Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K
Int J Drug Discov Pharm. 2025; 3(4).
PMID: 39926714
PMC: 11804271.
DOI: 10.53941/ijddp.2024.100022.
Zheng J, Wang S, Xia L, Sun Z, Chan K, Bernards R
Signal Transduct Target Ther. 2025; 10(1):35.
PMID: 39915447
PMC: 11802921.
DOI: 10.1038/s41392-024-02075-w.
Luo X, Li C, Qin G
Hereditas. 2025; 162(1):17.
PMID: 39910672
PMC: 11800565.
DOI: 10.1186/s41065-025-00380-0.
Single cell suppression profiling of human regulatory T cells.
Sondergaard J, Tulyeu J, Priest D, Sakaguchi S, Wing J
Nat Commun. 2025; 16(1):1325.
PMID: 39900891
PMC: 11791207.
DOI: 10.1038/s41467-024-55746-1.
Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study.
Plomp L, Chassepot H, Psimaras D, Maisonobe T, Mensi E, Leonard-Louis S
Lancet Reg Health Eur. 2025; 50:101192.
PMID: 39896961
PMC: 11782875.
DOI: 10.1016/j.lanepe.2024.101192.
PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration.
Kantheti U, Forward T, Lucas E, Schafer J, Tamburini P, Burchill M
Sci Adv. 2025; 11(5):eadt3044.
PMID: 39879305
PMC: 11777207.
DOI: 10.1126/sciadv.adt3044.
NIPAL1 as a prognostic biomarker associated with pancreatic adenocarcinoma progression and immune infiltration.
Zhu Y, Qi Z, Zu S, Yang F, Wang Y, Zhu L
BMC Cancer. 2025; 25(1):165.
PMID: 39875873
PMC: 11776251.
DOI: 10.1186/s12885-025-13567-5.
Investigating the functional and structural effect of non-synonymous single nucleotide polymorphisms in the cytotoxic T-lymphocyte antigen-4 gene: An in-silico study.
Kamal M, Shantanu K, Teeya S, Rahman M, Hasan A, Chivers D
PLoS One. 2025; 20(1):e0316465.
PMID: 39854591
PMC: 11759363.
DOI: 10.1371/journal.pone.0316465.
Treatment of immune checkpoint inhibitor-related colitis: a narrative review.
Wang S, Wang H
Transl Cancer Res. 2025; 13(12):7002-7014.
PMID: 39816545
PMC: 11729759.
DOI: 10.21037/tcr-24-2150.
The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy.
Li G, Che X, Wang S, Liu D, Xie D, Jiang B
Ann Med. 2025; 57(1):2447403.
PMID: 39757995
PMC: 11705547.
DOI: 10.1080/07853890.2024.2447403.
From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases.
Bulliard Y, Freeborn R, Uyeda M, Humes D, Bjordahl R, de Vries D
Front Immunol. 2024; 15:1509956.
PMID: 39697333
PMC: 11653210.
DOI: 10.3389/fimmu.2024.1509956.
Advancing immunosuppression in liver transplantation: the role of regulatory T cells in immune modulation and graft tolerance.
Han J, Park S
Clin Transplant Res. 2024; 38(4):257-272.
PMID: 39696994
PMC: 11732766.
DOI: 10.4285/ctr.24.0059.
Harnessing the biology of regulatory T cells to treat disease.
Wardell C, Boardman D, Levings M
Nat Rev Drug Discov. 2024; 24(2):93-111.
PMID: 39681737
DOI: 10.1038/s41573-024-01089-x.
The 'T paradox' in inflammatory arthritis.
Schnell J, Briviesca R, Kim T, Charbonnier L, Henderson L, van Wijk F
Nat Rev Rheumatol. 2024; 21(1):9-21.
PMID: 39653758
DOI: 10.1038/s41584-024-01190-w.
Co-evolution of glioma and immune microenvironment.
Elguindy M, Young J, Ho W, Lu R
J Immunother Cancer. 2024; 12(12.
PMID: 39631850
PMC: 11624716.
DOI: 10.1136/jitc-2024-009175.
Multimodal single cell-resolved spatial proteomics reveal pancreatic tumor heterogeneity.
Xu Y, Wang X, Li Y, Mao Y, Su Y, Mao Y
Nat Commun. 2024; 15(1):10100.
PMID: 39572534
PMC: 11582669.
DOI: 10.1038/s41467-024-54438-0.
Ferroptosis contributes to immunosuppression.
He N, Yuan D, Luo M, Xu Q, Wen Z, Wang Z
Front Med. 2024; 19(1):1-22.
PMID: 39560919
DOI: 10.1007/s11684-024-1080-8.
Depletion of conventional CD4 T cells is required for robust priming and dissemination of tumor antigen-specific CD8 T cells in the setting of anti-CD4 therapy.
Ramirez D, Dragnev C, Searles T, Spicer N, Chen T, Lines J
J Immunother Cancer. 2024; 12(11).
PMID: 39521617
PMC: 11552015.
DOI: 10.1136/jitc-2024-010170.